Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MMP13 | P45452 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 6/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.48 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2319308 | 0.89 | MEN1 (0.61) | POLBL3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL2314890 | 0.88 | MEN1 (0.62) | POLBL3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL2317979 | 0.88 | L3MBTL1 (0.51) | POLBL3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL2318753 | 0.88 | SCD (0.54) | POLBL3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL2314925 | 0.87 | ALDH1A1 (0.56) | POLBL3MBTL1MMP13MEN1KMT2A | |
| SCHEMBL2314629 | 0.86 | SCD (0.59) | POLBL3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL2317224 | 0.85 | MMP13 (0.59) | POLBL3MBTL1MMP13MEN1KMT2A | |
| SCHEMBL2316691 | 0.80 | ALDH1A1 (0.56) | POLBL3MBTL1MMP13MEN1KMT2A | |
| SCHEMBL2312920 | 0.80 | MMP13 (0.60) | MMP13MEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL6302269 | 0.80 | MMP13 (0.60) | MMP13MEN1KMT2AHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350029-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS | Gilead Sciences, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010056230-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS | CV THERAPEUTICS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20090105283-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20080255161-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255161-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, ECHS1 | POLB 4378/4885L3MBTL1 1708/4885MMP13 2270/4885 |
| US-20090105283-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, ECHS1 | POLB 4378/4885L3MBTL1 1708/4885MMP13 2270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.